Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Arrhythmias

  Free Subscription


Articles published in J Thromb Thrombolysis

Retrieve available abstracts of 50 articles:
HTML format
Text format



Single Articles


    September 2019
  1. GULILAT M, Keller D, Linton B, Pananos AD, et al
    Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.
    J Thromb Thrombolysis. 2019 Sep 28. pii: 10.1007/s11239-019-01962.
    PubMed     Text format     Abstract available


    August 2019
  2. WOJSZEL ZB, Kasiukiewicz A
    Determinants of anticoagulant therapy in atrial fibrillation at discharge from a geriatric ward: cross sectional study.
    J Thromb Thrombolysis. 2019 Aug 30. pii: 10.1007/s11239-019-01937.
    PubMed     Text format     Abstract available


  3. IKEDA T, Ogawa S, Kitazono T, Nakagawara J, et al
    Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
    J Thromb Thrombolysis. 2019 Aug 20. pii: 10.1007/s11239-019-01934.
    PubMed     Text format     Abstract available


  4. RUSSO V, Attena E, Di Maio M, Mazzone C, et al
    Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    J Thromb Thrombolysis. 2019 Aug 5. pii: 10.1007/s11239-019-01923.
    PubMed     Text format     Abstract available


    July 2019
  5. SAMOS M, Bolek T, Skornova I, Benko J, et al
    Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?
    J Thromb Thrombolysis. 2019 Jul 1. pii: 10.1007/s11239-019-01910.
    PubMed     Text format     Abstract available


    June 2019
  6. MIAO B, Alberts MJ, Bunz TJ, Coleman CI, et al
    Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
    J Thromb Thrombolysis. 2019 Jun 21. pii: 10.1007/s11239-019-01898.
    PubMed     Text format     Abstract available


  7. OSMAN M, Kheiri B, Munir MB, Moreland JA, et al
    The fading role of triple therapy in patients with atrial fibrillation and acute coronary syndrome: a Bayesian network meta-analysis.
    J Thromb Thrombolysis. 2019 Jun 7. pii: 10.1007/s11239-019-01896.
    PubMed     Text format    


  8. KE HH, He Y, Lv XW, Zhang EH, et al
    Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients.
    J Thromb Thrombolysis. 2019 Jun 5. pii: 10.1007/s11239-019-01876.
    PubMed     Text format     Abstract available


    May 2019
  9. GRUCA MM, Li Y, Kong X, DeCamillo D, et al
    Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2019 May 20. pii: 10.1007/s11239-019-01883.
    PubMed     Text format     Abstract available


  10. KHEIRI B, Osman M, Bakhit A, Radaideh Q, et al
    Dual versus triple therapy for patients with atrial fibrillation and acute coronary syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials.
    J Thromb Thrombolysis. 2019 May 3. pii: 10.1007/s11239-019-01874.
    PubMed     Text format    


    April 2019
  11. GUIMARAES PO, Lopes RD, Alexander JH, Thomas L, et al
    International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin.
    J Thromb Thrombolysis. 2019 Apr 10. pii: 10.1007/s11239-019-01858.
    PubMed     Text format     Abstract available


  12. SCHOAPS RS, Quintili A, Bonavia A, Carr ZJ, et al
    Stroke prophylaxis in critically-ill patients with new-onset atrial fibrillation.
    J Thromb Thrombolysis. 2019 Apr 8. pii: 10.1007/s11239-019-01854.
    PubMed     Text format     Abstract available


  13. OKISHIGE K, Yamauchi Y, Hanaki Y, Inoue K, et al
    Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation.
    J Thromb Thrombolysis. 2019 Apr 6. pii: 10.1007/s11239-019-01835.
    PubMed     Text format     Abstract available


  14. WASHAM JB, Hohnloser SH, Lopes RD, Wojdyla DM, et al
    Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.
    J Thromb Thrombolysis. 2019;47:345-352.
    PubMed     Text format     Abstract available


    March 2019
  15. AMIN A, Keshishian A, Dina O, Dhamane A, et al
    Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    J Thromb Thrombolysis. 2019 Mar 28. pii: 10.1007/s11239-019-01838.
    PubMed     Text format     Abstract available


  16. CROSTA F, Desideri G, Marini C
    Leukoaraiosis is an independent predictor of intracranial hemorrhage in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2019 Mar 14. pii: 10.1007/s11239-019-01839.
    PubMed     Text format     Abstract available


  17. KARTAS A, Samaras A, Vasdeki D, Dividis G, et al
    Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation.
    J Thromb Thrombolysis. 2019 Mar 4. pii: 10.1007/s11239-019-01832.
    PubMed     Text format     Abstract available


    February 2019
  18. STANKOVIC P, Georgiew R, Frommelt C, Hammel S, et al
    Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.
    J Thromb Thrombolysis. 2019 Feb 7. pii: 10.1007/s11239-019-01824.
    PubMed     Text format     Abstract available


  19. BJORCK F, Kadhim H, Sjalander A
    Predictors for INR-control in a well-managed warfarin treatment setting.
    J Thromb Thrombolysis. 2019;47:227-232.
    PubMed     Text format     Abstract available


    January 2019
  20. HIRSH RACCAH B, Rottenstreich A, Zacks N, Matok I, et al
    Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients.
    J Thromb Thrombolysis. 2019 Jan 28. pii: 10.1007/s11239-019-01815.
    PubMed     Text format     Abstract available


    December 2018
  21. WANG CL, Wu VC, Lee CH, Kuo CF, et al
    Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia.
    J Thromb Thrombolysis. 2018 Dec 18. pii: 10.1007/s11239-018-1792.
    PubMed     Text format     Abstract available


    November 2018
  22. MASOTTI L, Grifoni E, Dei A, Vannucchi V, et al
    Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: focus on real life studies.
    J Thromb Thrombolysis. 2018 Nov 23. pii: 10.1007/s11239-018-1775.
    PubMed     Text format     Abstract available


  23. HOWE Z, Naville-Cook C, Cole D
    Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    J Thromb Thrombolysis. 2018 Nov 17. pii: 10.1007/s11239-018-1770.
    PubMed     Text format     Abstract available


  24. CHOPARD R, Piazza G, Hurwitz S, Fanikos J, et al
    Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients.
    J Thromb Thrombolysis. 2018 Nov 17. pii: 10.1007/s11239-018-1767.
    PubMed     Text format     Abstract available


    October 2018
  25. BOLEK T, Samos M, Skornova I, Stanciakova L, et al
    Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.
    J Thromb Thrombolysis. 2018 Oct 4. pii: 10.1007/s11239-018-1748.
    PubMed     Text format     Abstract available


  26. SOKOL J, Nehaj F, Ivankova J, Mokan M, et al
    First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation.
    J Thromb Thrombolysis. 2018;46:393-398.
    PubMed     Text format     Abstract available


  27. CAPPELLARI M, Turcato G, Forlivesi S, Micheletti N, et al
    Introduction of direct oral anticoagulant within 7 days of stroke onset: a nomogram to predict the probability of 3-month modified Rankin Scale score > 2.
    J Thromb Thrombolysis. 2018;46:292-298.
    PubMed     Text format     Abstract available


    September 2018
  28. HIRSH RACCAH B, Rottenstreich A, Zacks N, Muszkat M, et al
    Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients.
    J Thromb Thrombolysis. 2018 Sep 8. pii: 10.1007/s11239-018-1738.
    PubMed     Text format     Abstract available


    August 2018
  29. MAZUR P, Myc J, Natorska J, Plens K, et al
    Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.
    J Thromb Thrombolysis. 2018;46:193-202.
    PubMed     Text format     Abstract available


  30. POLNAK JF, Delate T, Clark NP
    The influence of fibrate initiation on INR and warfarin dose in patients receiving chronic warfarin therapy.
    J Thromb Thrombolysis. 2018;46:264-270.
    PubMed     Text format     Abstract available


  31. SHIROSHITA A, Nakashima K, Tanaka Y, Tateishi A, et al
    Successful treatment with idarucizumab for diffuse alveolar hemorrhage induced by dabigatran etexilate: a case report.
    J Thromb Thrombolysis. 2018;46:271-273.
    PubMed     Text format     Abstract available


    July 2018
  32. JACKSON LR 2ND, Kim S, Shrader P, Blanco R, et al
    Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
    J Thromb Thrombolysis. 2018 Jul 26. pii: 10.1007/s11239-018-1715.
    PubMed     Text format     Abstract available


  33. AGIRBASLI M
    Quality of direct oral anticoagulant therapy in elderly patients with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2018 Jul 25. pii: 10.1007/s11239-018-1717.
    PubMed     Text format    


    June 2018
  34. CHI G, Yee MK, Kalayci A, Kerneis M, et al
    Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
    J Thromb Thrombolysis. 2018 Jun 26. pii: 10.1007/s11239-018-1703.
    PubMed     Text format     Abstract available


  35. KHEIRI B, Haykal T, Abdalla A, Osman M, et al
    Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis.
    J Thromb Thrombolysis. 2018 Jun 15. pii: 10.1007/s11239-018-1694.
    PubMed     Text format    


  36. HUGHEY AB, Gu X, Haymart B, Kline-Rogers E, et al
    Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)) registry to the RE-LY, ROCKET-AF, and ARISTOTLE
    J Thromb Thrombolysis. 2018 Jun 14. pii: 10.1007/s11239-018-1698.
    PubMed     Text format     Abstract available


  37. MONAGLE SR, Hirsh J, Bhagirath VC, Ginsberg JS, et al
    Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada.
    J Thromb Thrombolysis. 2018 Jun 5. pii: 10.1007/s11239-018-1692.
    PubMed     Text format     Abstract available


    May 2018
  38. ROSSI AP, Facchinetti R, Ferrari E, Nori N, et al
    Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2018 May 14. pii: 10.1007/s11239-018-1679.
    PubMed     Text format     Abstract available


  39. HOYER C, Filipov A, Neumaier-Probst E, Szabo K, et al
    Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke.
    J Thromb Thrombolysis. 2018;45:529-535.
    PubMed     Text format     Abstract available


  40. FASULLO S, Davi S, Cosenza G, Di Franco F, et al
    Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature.
    J Thromb Thrombolysis. 2018;45:588-592.
    PubMed     Text format     Abstract available


    April 2018
  41. GRANT SJ, Kothari S, Gimotty PA, Gooneratne NS, et al
    Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.
    J Thromb Thrombolysis. 2018 Apr 2. pii: 10.1007/s11239-018-1651.
    PubMed     Text format     Abstract available


    February 2018
  42. BRUNETTI ND, Tarantino N, De Gennaro L, Correale M, et al
    Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis.
    J Thromb Thrombolysis. 2018 Feb 5. pii: 10.1007/s11239-018-1622.
    PubMed     Text format     Abstract available


    January 2018
  43. XIANG E, Ahuja T, Raco V, Cirrone F, et al
    Anticoagulation prescribing patterns in patients with cancer.
    J Thromb Thrombolysis. 2018;45:89-98.
    PubMed     Text format     Abstract available


    December 2017
  44. RUSSO V, Rago A, Papa AA, D'Onofrio A, et al
    Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.
    J Thromb Thrombolysis. 2017 Dec 19. pii: 10.1007/s11239-017-1599.
    PubMed     Text format     Abstract available


  45. SHIN H, Cho MC, Kim RB, Kim CH, et al
    Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2017 Dec 2. pii: 10.1007/s11239-017-1590.
    PubMed     Text format     Abstract available


    July 2017
  46. PIPILIS A, Makrygiannis S, Anagnostou G, Kaliampakos S, et al
    Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures.
    J Thromb Thrombolysis. 2017;44:9-13.
    PubMed     Text format     Abstract available


    June 2017
  47. HELMERT S, Marten S, Mizera H, Reitter A, et al
    Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
    J Thromb Thrombolysis. 2017 Jun 22. doi: 10.1007/s11239-017-1519.
    PubMed     Text format     Abstract available


    March 2017
  48. STEPPICH B, Dobler F, Brendel LC, Hessling G, et al
    Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2017 Mar 18. doi: 10.1007/s11239-017-1495.
    PubMed     Text format     Abstract available


    February 2017
  49. MARSICO F, Cecere M, Parente A, Paolillo S, et al
    Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal.
    J Thromb Thrombolysis. 2017;43:139-148.
    PubMed     Text format     Abstract available


    August 2016
  50. ROSWELL RO, Greet B, Shah S, Bernard S, et al
    Intravenous heparin dosing strategy in hospitalized patients with atrial dysrhythmias.
    J Thromb Thrombolysis. 2016;42:179-85.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: